Clinical Trials for Ovarian Cancer

A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable or metastatic solid tumors other than NSCLC that harbor an activating HER2 mutation are eligible after appropriate standard therapy or when no satisfactory alternative exists; prior HER2 tyrosine kinase inhibitor treatment and active brain metastases are excluded. All participants receive oral sevabertinib, a reversible HER2-directed tyrosine kinase inhibitor, 20 mg twice daily.

ClinicalTrials.gov ID: NCT06760819

A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This study enrolls patients with measurable, progressive or recurrent platinum-resistant ovarian cancer after 1–3 prior lines of therapy, or clear cell gynecologic cancer after at least one prior line; prior checkpoint inhibitor therapy is excluded. All participants receive intravenous lorigerlimab, an investigational bispecific antibody targeting PD-1 and CTLA-4.

ClinicalTrials.gov ID: NCT06730347

An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, and a Substudy Evaluating PIKTOR With Paclitaxel Plus an Insulin-Suppressing Diet, in Patients With Advanced or Recurrent Endometrial Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Patients with unresectable advanced or recurrent endometrioid endometrial carcinoma, a PI3K/AKT/mTOR pathway alteration, and 1–4 prior systemic therapies, generally including platinum chemotherapy and a checkpoint inhibitor, receive paclitaxel plus sapanisertib (an mTORC1/2 inhibitor) and serabelisib (a PI3Kα inhibitor). A substudy adds an insulin-suppressing diet.

ClinicalTrials.gov ID: NCT06463028

A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Women with previously untreated FIGO stage IIIB/C or IV high-grade non-mucinous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are candidates for neoadjuvant chemotherapy are randomized to carboplatin/paclitaxel with or without intraperitoneal IMNN-001, followed by interval debulking surgery, adjuvant chemotherapy, and standard maintenance therapy. IMNN-001 is a lipopolymer-delivered plasmid encoding interleukin-12, intended to stimulate a local antitumor immune response.

ClinicalTrials.gov ID: NCT06915025

A Phase 2 Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent or persistent ARID1A-mutated ovarian, fallopian tube, or primary peritoneal cancer with predominantly clear cell or endometrioid morphology and measurable disease are eligible after at least two cytotoxic regimens or with platinum-resistant/refractory disease; prior PARP inhibitor or temozolomide use is excluded. Treatment combines senaparib, a PARP1/2 inhibitor, with temozolomide, a DNA-alkylating agent.

ClinicalTrials.gov ID: NCT06617923

Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This study enrolls women with CLDN6-positive, platinum-resistant, unresectable or metastatic high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer after 1–3 prior systemic treatment lines. All listed cohorts receive ixotatug vedotin (TORL-1-23), an investigational CLDN6-targeting antibody–drug conjugate that delivers the microtubule-disrupting payload MMAE, plus pegfilgrastim.

ClinicalTrials.gov ID: NCT06690775

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: For patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after six cycles of second-line carboplatin-based doublet chemotherapy, this study compares maintenance sacituzumab tirumotecan, with or without bevacizumab, against local standard-of-care maintenance with optional bevacizumab. Sacituzumab tirumotecan is an investigational TROP2-targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor.

ClinicalTrials.gov ID: NCT06824467

A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This single-arm study enrolls patients with cyclin E1–overexpressing, platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer after 1–4 prior systemic therapies; prior bevacizumab is generally required, and primary platinum-refractory disease is excluded. All patients receive INCB123667, an investigational oral CDK2 inhibitor targeting the cyclin E1–CDK2 pathway.

ClinicalTrials.gov ID: NCT07023627

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Patients with measurable recurrent low-grade serous ovarian, fallopian tube, or peritoneal cancer after prior systemic therapy, including platinum, are randomized to oral avutometinib (a RAF–MEK signaling inhibitor) plus defactinib (a FAK inhibitor) or investigator’s choice of pegylated liposomal doxorubicin, paclitaxel, letrozole, or anastrozole. Documented KRAS status and ECOG performance status 0–1 are required.

ClinicalTrials.gov ID: NCT06072781

Combination Targeted and Hormonal treAtMEnt of Low-gradE Serous Ovarian Cancer in the upfroNt Setting

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with measurable, previously untreated low-grade serous ovarian or peritoneal cancer who are not candidates for primary debulking or have measurable disease after attempted debulking receive upfront avutometinib (RAF–MEK pathway inhibitor), defactinib (FAK inhibitor), and letrozole. Premenopausal or perimenopausal patients with an ovary in situ also receive leuprolide for ovarian suppression.

ClinicalTrials.gov ID: NCT06394804